Comparative Evaluation of Renoprotective Drug Regimens in Patients With Early-Stage Diabetic Kidney Disease

A conceptual framework is presented to compare the mechanisms and theoretical effects of major renoprotective drug regimens used in the early stages of diabetic kidney disease. The condition develops through interconnected hemodynamic, metabolic, inflammatory, and fibrotic processes, and the therapeutic agents examined here influence different components of these pathways. The framework brings together established scientific knowledge on drug actions and the biological factors that drive early renal injury, offering a structured perspective on how each therapy may contribute to renal protection. Emphasis is placed on the importance of early therapeutic intervention, since kidney damage frequently begins before measurable declines in kidney function appear. The analysis also highlights the potential value of combining therapeutic agents to address multiple disease pathways at once. Overall, the framework supports improved treatment decision-making, encourages personalized therapeutic strategies, and identifies future research needs for empirical validation and comparative assessment of integrated drug regimens for early diabetic kidney disease.